European companies raised their R&D spending by 5.3 per cent last year - but still failed to keep up with bigger-spending U.S. and Asian competitors in the global R&D market, data from a European Commission study suggest.
The 2006 EU Industrial R&D Investment Scoreboard provides information of the top 1000 EU companies and top 1000 from outside the EU (non-EU) which invest the most in R&D.
After months of talking, Imperial College London and the University of London set terms for their separation - a major break-up among R&D heavyweights.
A small number of German universities will next week receive a large boost in fame and fortune as Germany seeks to restore the fortunes of its science.
These days, Big Pharma does not appear to have many friends. The market performance of many big pharmaceutical companies has been middling, as the sector’s competitive position is perceived to be under several threats. The drug pipeline appears to be drying up and geared more toward lifestyle enhancement than life savings. Costly and reputation-damaging liability suits are proliferating. Pricing pressures are relentless. They come from pressure groups such as AIDS patients; but they are reinforced by public authorities, not only in the developing world but also in the US and in Europe, as governments seek to slow down the relentless progress of health expenditures.
An obsession with the equity gap is obscuring the real reasons why universities are failing to commercialise their research, says one of the UK's leading spin-out investors.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.